<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271985</url>
  </required_header>
  <id_info>
    <org_study_id>DDRC.89.17</org_study_id>
    <nct_id>NCT01271985</nct_id>
  </id_info>
  <brief_title>Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPill</brief_title>
  <acronym>PolyIran</acronym>
  <official_title>Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Golestan University of Medical Science</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of PolyPill tablet (a fixed dose
      combination of two anti-hypertensive medications, atorvastatin and aspirin) on primary and
      secondary prevention of cardiovascular disease in Iranian adults older than 50.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular diseases (myocardial infarction and stroke) are the most common cause of death
      and disability in Iran and account for nearly half of all-cause mortality in Iranians.
      Therefore, prevention of cardiovascular diseases is a top priority in countries with limited
      health system budgets such as Iran.

      Eighty seven to hundred percent of patients dying from Coronary Heart Disease (CHD) have at
      least one risk factor for cardiovascular diseases. Therefore, risk factor modification in
      middle-aged and old individuals might prevent death and is a main priority. Combination drug
      therapy has been proposed as a cost-effective measure to reduce modifiable risk factors for
      cardiovascular disease in aged people. It has been showed that combination drug therapy can
      potentially decrease ischemic heart events and strokes by 88 and 80 percent, respectively.

      The purpose of this study is to determine the effects of PolyPill tablet (a fixed dose
      combination of two anti-hypertensive medications, atorvastatin and aspirin) on primary and
      secondary prevention of cardiovascular disease in Iranian adults older than 50.

      This is a study on subjects older than 50 enrolled in the Golestan Cohort Study. The study is
      designed as a pragmatic cluster randomized trial. The study comprises three arms as follows:

        1. 3500 randomly selected participants receive PolyPill tablets once daily and Minimal care
           (which consists of direct education and pamphlet on cardiovascular risk reduction,
           biannual follow-ups and BP measurements).

        2. 3500 randomly selected participants receive only Minimal care as described above.

        3. 24000 participants receive usual care (the basic primary health care provided by the
           local physicians and Community Health Workers for the whole participants of Golestan
           Cohort study consistent with the current Iranian Health Care System guidelines).

      Arms #1 and #2 are compared via a 2-armed open-labeled cluster Randomized Controlled Trial.
      Comparisons between arm #3 and the other 2 arms are also performed.

      Endpoints include major cardiovascular events (death and hospitalization)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>February 2011</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first major cardiovascular event</measure>
    <time_frame>5 years</time_frame>
    <description>Major cardiovascular events are defined as:
Major coronary events include: sudden cardiac death, myocardial infarction, a diagnosis of angina, revascularization procedure
Cerebrovascular accidents (CVA) including transient ischemic attacks (TIA)
Hospitalization because of cardiovascular disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>5 years</time_frame>
    <description>Changes in blood pressure after 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting blood sugar, total cholesterol, HDL-C and LDL-C</measure>
    <time_frame>5 years</time_frame>
    <description>Changes in fasting blood sugar and lipid profile after 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Developing Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants who experience adverse effects to the PolyPill tablet leading to discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>5 years</time_frame>
    <description>Compliance is measured by pill-count in participants of the intervention arm as percent pills taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of major cardiovascular events</measure>
    <time_frame>5 years</time_frame>
    <description>Number of major cardiovascular events (as described above) during 5 years</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">7000</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>PolyPill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PolyPill once daily and Minimal Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Minimal care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minimal care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Basic primary health care provided by the local physicians and Community Health Workers consistent with the current Iranian Health Care System guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PolyPill</intervention_name>
    <description>A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily</description>
    <arm_group_label>PolyPill</arm_group_label>
    <other_name>PolyPill 4-1</other_name>
    <other_name>PolyPill 4-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Minimal care</intervention_name>
    <description>Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement</description>
    <arm_group_label>PolyPill</arm_group_label>
    <arm_group_label>Minimal care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50-79 years old

          -  Enrollment in the Golestan Cohort Study

        Exclusion Criteria:

          1. Hypersensitivity to any of PolyPill components:

               1. Hypersensitivity to Non-steroidal anti-inflammatory agents

               2. Hypersensitivity to statins

               3. Hypersensitivity to hydrochlorothiazide or sulfonamides

               4. Hypersensitivity to enalapril and valsartan

          2. Past medical history of angioedema

          3. Medical history of GI bleeding or peptic ulcer in the last 3 months

          4. Pregnancy or lactation

          5. Bleeding disorders such as hemophilia

          6. Receiving anticoagulation therapy

          7. Alcohol consumption greater than 40gr/week

          8. Advanced liver disease

          9. Uncontrolled seizures

         10. Asthma with any of the following criteria present:

               1. Daily symptoms

               2. Asthmatic attacks waking the patient from sleep more than once a week

               3. History of nasal polyps

               4. Aspirin sensitive asthma

               5. Presence of rhinitis symptoms not due to infection

         11. Past medical history of gout

         12. Serum creatinine values above 2 mg/dL or a Glomerular Filtration Rate (GFR) below 30
             mL/min

         13. Hemoglobin concentrations below 11 g/dL for males and 10 g/dL for females

         14. BP &lt; 90/60

         15. Debilitating medical/mental disorders affecting medication compliance (including
             psychosis, disabilities, and blindness)

         16. Past medical history of stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Malekzadeh, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Digestive Disease Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Golestan Cohort Study Center</name>
      <address>
        <city>Gonbad</city>
        <state>Golestan</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Malekzadeh F, Marshall T, Pourshams A, Gharravi M, Aslani A, Nateghi A, Rastegarpanah M, Khoshnia M, Semnani S, Salahi R, Thomas GN, Larijani B, Cheng KK, Malekzadeh R. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract. 2010 Aug;64(9):1220-7. doi: 10.1111/j.1742-1241.2010.02412.x.</citation>
    <PMID>20653798</PMID>
  </reference>
  <reference>
    <citation>Lonn E, Bosch J, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010 Nov 16;122(20):2078-88. doi: 10.1161/CIRCULATIONAHA.109.873232. Review.</citation>
    <PMID>21098469</PMID>
  </reference>
  <reference>
    <citation>Lonn E, Yusuf S. Polypill: the evidence and the promise. Curr Opin Lipidol. 2009 Dec;20(6):453-9. doi: 10.1097/MOL.0b013e32833305a3. Review.</citation>
    <PMID>19884824</PMID>
  </reference>
  <reference>
    <citation>Malekzadeh F, Pourshams A, Marshall T. The preventive polypill--much promise, insufficient evidence. Arch Iran Med. 2007 Jul;10(3):430-1.</citation>
    <PMID>17604490</PMID>
  </reference>
  <reference>
    <citation>Majed M, Moradmand Badie S. A pilot double-blind randomised placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Arch Iran Med. 2011 Jan;14(1):78-80. doi: 011141/AIM.0020.</citation>
    <PMID>21194270</PMID>
  </reference>
  <reference>
    <citation>PILL Collaborative Group, Rodgers A, Patel A, Berwanger O, Bots M, Grimm R, Grobbee DE, Jackson R, Neal B, Neaton J, Poulter N, Rafter N, Raju PK, Reddy S, Thom S, Vander Hoorn S, Webster R. An international randomised placebo-controlled trial of a four-component combination pill (&quot;polypill&quot;) in people with raised cardiovascular risk. PLoS One. 2011;6(5):e19857. doi: 10.1371/journal.pone.0019857. Epub 2011 May 25.</citation>
    <PMID>21647425</PMID>
  </reference>
  <reference>
    <citation>Indian Polycap Study (TIPS), Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009 Apr 18;373(9672):1341-51. doi: 10.1016/S0140-6736(09)60611-5. Epub 2009 Mar 30.</citation>
    <PMID>19339045</PMID>
  </reference>
  <reference>
    <citation>Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003 Jun 28;326(7404):1419. Erratum in: BMJ. 2006 Sep;60(9):823. BMJ. 2003 Sep 13;327(7415):586.</citation>
    <PMID>12829553</PMID>
  </reference>
  <reference>
    <citation>Wald DS, Wald NJ. Implementation of a simple age-based strategy in the prevention of cardiovascular disease: the Polypill approach. J Eval Clin Pract. 2012 Jun;18(3):612-5. doi: 10.1111/j.1365-2753.2011.01637.x. Epub 2011 Jan 30.</citation>
    <PMID>21276141</PMID>
  </reference>
  <reference>
    <citation>Wald DS, Wald NJ. The Polypill in the prevention of cardiovascular disease. Prev Med. 2011 Jan;52(1):16-7. doi: 10.1016/j.ypmed.2010.11.015. Epub 2010 Dec 2.</citation>
    <PMID>21130112</PMID>
  </reference>
  <reference>
    <citation>Rifai L, Khan BV. Do the current medical and economic times dictate the need for the &quot;polypill&quot;? J Clin Hypertens (Greenwich). 2009 Dec;11(12):775-6. doi: 10.1111/j.1751-7176.2009.00188.x.</citation>
    <PMID>20021541</PMID>
  </reference>
  <reference>
    <citation>Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, Furberg CD. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials. 2011 Jan 5;12:3. doi: 10.1186/1745-6215-12-3.</citation>
    <PMID>21205325</PMID>
  </reference>
  <reference>
    <citation>Sepanlou SG, Poustchi H, Kamangar F, Malekzadeh R. Effectiveness and feasibility of lifestyle and low-cost pharmacologic interventions in the prevention of chronic diseases: a review. Arch Iran Med. 2011 Jan;14(1):46-53. doi: 011141/AIM.0010. Review.</citation>
    <PMID>21194261</PMID>
  </reference>
  <reference>
    <citation>Sepanlou SG, Kamangar F, Poustchi H, Malekzadeh R. Reducing the burden of chronic diseases: a neglected agenda in Iranian health care system, requiring a plan for action. Arch Iran Med. 2010 Jul;13(4):340-50. doi: 010134/AIM.0015. Review.</citation>
    <PMID>20597569</PMID>
  </reference>
  <reference>
    <citation>Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. Nat Clin Pract Cardiovasc Med. 2009 Feb;6(2):101-10. doi: 10.1038/ncpcardio1419. Epub 2008 Dec 23. Review.</citation>
    <PMID>19104519</PMID>
  </reference>
  <reference>
    <citation>Robinson JG, Maheshwari N. A &quot;poly-portfolio&quot; for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol. 2005 Feb 1;95(3):373-8.</citation>
    <PMID>15670547</PMID>
  </reference>
  <reference>
    <citation>Sarrafzadegan N, Talaei M, Sadeghi M, Kelishadi R, Oveisgharan S, Mohammadifard N, Sajjadieh AR, Kabiri P, Marshall T, Thomas GN, Tavasoli A. The Isfahan cohort study: rationale, methods and main findings. J Hum Hypertens. 2011 Sep;25(9):545-53. doi: 10.1038/jhh.2010.99. Epub 2010 Nov 25.</citation>
    <PMID>21107436</PMID>
  </reference>
  <reference>
    <citation>Sanson-Fisher RW, Bonevski B, Green LW, D'Este C. Limitations of the randomized controlled trial in evaluating population-based health interventions. Am J Prev Med. 2007 Aug;33(2):155-61. Review.</citation>
    <PMID>17673104</PMID>
  </reference>
  <reference>
    <citation>Relton C, Torgerson D, O'Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the &quot;cohort multiple randomised controlled trial&quot; design. BMJ. 2010 Mar 19;340:c1066. doi: 10.1136/bmj.c1066.</citation>
    <PMID>20304934</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>May 6, 2014</last_update_submitted>
  <last_update_submitted_qc>May 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Drug Combinations</keyword>
  <keyword>prevention and control</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Antihypertensive Agents</keyword>
  <keyword>Antilipemic Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

